Therapeutic effect of clarithromycin for respiratory-tract infections in children caused by Chlamydia pneumoniae

Numazaki, Kei; Sakamoto, Yoshinori; Umetsu, Masao; Agatsuma, Yoshitaka; Yamanaka, Tatsuru; Kogasaka, Ryoich; Hiraki, Masahisa; Kuniya, Yoshinori; Miua, Junichi; Ukae, Susumu; Ueda, Daisuke; Sato, Toshiya; Chiba, Shunzo

doi:10.1016/s0924-8579(99)00116-8

Cited by 7 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the optimum mode and duration of therapy has not been determined, 33 early instigation of appropriate therapy 34,35 seems desirable based on our experience. A possible immunomodulatory effect of macrolides on the airway epithelium is of particular relevance after LTx, wherein the major cause of long-term morbidity and mortality is inflammatory airway disease.…”

Section: Discussionmentioning

confidence: 99%

Chlamydia pneumoniae infection after lung transplantation

Glanville¹,

Gencay²,

Tamm³

et al. 2005

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Chlamydia pneumoniae infection after lung transplantation

Glanville¹,

Gencay²,

Tamm³

et al. 2005

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

“…clarithromycin [22][23][24][25][26], and azithromycin [33][34][35][36][37][38][39] and these drugs treat the infections caused by different bacteria. Erythromycin [13,14], clarithromycin [27], and azithromycin [14] are poorly transferred across the human placenta and erythromycin [15], clarithromycin [28], and azithromycin [41] poorly migrate into the breast milk.…”

Section: Discussionmentioning

confidence: 99%

“…Clarithromycin therapy reduces mucosal tumour necrosis factor α, interleukin-1β, and interleukin-10 concentrations in children with an acute exacerbation of recurrent wheezing [25]. Administration of clarithromycin is a suitable treatment for improving lower respiratory infections in infants and children caused by Chlamydia pneumoniae [26].…”

Section: Treatment Of Bacterial Infections With Clarithromycinmentioning

confidence: 99%

"Clinical Pharmacology of Macrolides in Infants and Children"

Pacific¹

2022

BJSTR

View full text Add to dashboard Cite

Macrolides used in paediatric patients are: erythromycin, clarithromycin, and azithromycin. The oral dose of erythromycin for children is 30 to 50 mg/kg daily divided into 4 portions. Clarithromycin usually is given twice-daily at a dose of 250 for adults with mild-to-moderate infections. In children, the recommended dose of azithromycin oral suspension for treating acute otitis media and pneumonia is 10 mg/kg on the first day (maximum 500 mg) and 5 mg (maximum 20 mg daily) on days 2 through 5. The dosing of erythromycin, clarithromycin, and azithromycin has been extensively described. The efficacy and safety of erythromycin, clarithromycin, and azithromycin have been reported. The pharmacokinetics of erythromycin estolate and ethylsuccinate have been studied in infants and the elimination half-life at the steady state is 6.56 and 2.34 hours, respectively. The pharmacokinetics of clarithromycin have been studied in infants and children, and the elimination half-life is about 4 hours. The pharmacokinetics of azithromycin have been studied in infants and children and the mean elimination half-life is 31.6 hours. The treatment of bacterial infections with erythromycin, clarithromycin, and azithromycin has been reported. Erythromycin, clarithromycin, and azithromycin poorly cross the human placenta and poorly migrate into the breast milk. The aim of this study is to review the dosing, pharmacokinetics, treatment, transfer across the human placenta, and the migration into the breast milk of erythromycin, clarithromycin, and azithromycin.

show abstract